Mirum discontinues OHANA Phase 2b trial of volixibat in ICP due to enrollment feasibility

Mirum Pharmaceuticals, Inc.

Discontinued Phase 2b OHANA trial of volixibat for intrahepatic cholestasis of pregnancy (ICP).
Interim analysis showed meaningful reductions in serum bile acids and pruritus in treated patients.
Decision driven by unique enrollment challenges in high-risk pregnancy setting.
Company will prioritize other pipeline programs following the discontinuation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.